Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14034809 | 0.86 | PDE10A (0.44) | S1PR4KDM4EALDH1A1GAATDP1 | |
| SCHEMBL3075399 | 0.85 | KDM4E (0.59) | S1PR4KDM4EALDH1A1GAATDP1 | |
| SCHEMBL8284459 | 0.83 | KDM4E (0.42) | S1PR4KDM4EALDH1A1TDP1MAPT | |
| SCHEMBL3067223 | 0.83 | KDM4E (0.42) | S1PR4KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL16230349 | 0.80 | S1PR4 (0.53) | S1PR4KDM4EALDH1A1GAATDP1 | |
| SCHEMBL14003102 | 0.80 | KDM4E (0.40) | S1PR4KDM4EALDH1A1GAATDP1 | |
| SCHEMBL15099894 | 0.79 | ALDH1A1 (0.47) | KDM4EALDH1A1GAATDP1MEN1 | |
| SCHEMBL24198888 | 0.78 | S1PR4 (0.50) | S1PR4KDM4EALDH1A1GAATDP1 | |
| SCHEMBL9886153 | 0.76 | KDM4E (0.39) | S1PR4KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7921987 | 0.76 | KDM4E (0.39) | KDM4EALDH1A1MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| WO-2018109202-A1 | MONOCYCLIC OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
| CN-104254525-B | aromatic ring compound | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2016-05-25 | — | — | CN | disclosed |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. | 2016-02-18 | — | — | US | disclosed |
| WO-2016022464-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-8883837-B2 | Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-11 | — | — | US | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8044073-B2 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-25 | — | — | US | disclosed |
| US-8044073-B2 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-25 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7737295-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| EP-1697345-B1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-05-03 | — | — | US | disclosed |
| WO-2005058869-A1 | AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 | S1PR4 4471/4885KDM4E 704/4885ALDH1A1 1319/4885 |
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | S1PR4 1006/4885KDM4E 2716/4885ALDH1A1 2315/4885 |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | S1PR4 955/4885KDM4E 3516/4885ALDH1A1 3985/4885 |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | S1PR4 4818/4885KDM4E 679/4885ALDH1A1 2350/4885 |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | MAVS, EIF2AK2, SARS1 | S1PR4 964/4885KDM4E 4080/4885ALDH1A1 2576/4885 |
| US-20100249024-A1 | CETP INHIBITORS | CETP, APOB, NPC1 | S1PR4 1006/4885KDM4E 2716/4885ALDH1A1 2315/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | S1PR4 1001/4885KDM4E 1437/4885ALDH1A1 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.